David Hering, Invivyd CEO
March 25, 2024 10:50 AM EDTUpdated March 26, 01:10 PM
R&D

In­vivyd scores EUA for Covid-19 pre­ven­tion drug Pem­gar­da

Katherine Lewin

News Reporter

The FDA gave the green light to In­vivyd’s Pem­gar­da for Covid-19 pre­ven­tion in high-risk im­muno­com­pro­mised pa­tients, is­su­ing an emer­gency use au­tho­riza­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times